12 hours ago
Kepler Capital Keeps Their Buy Rating on Hyloris Pharmaceuticals SA (52U)
Kepler Capital analyst Christophe dombu maintained a Buy rating on Hyloris Pharmaceuticals SA (52U – Research Report) on June 17 and set a price target of €16.00. The company's shares closed last Monday at €5.68.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, dombu is an analyst with an average return of -6.8% and a 37.50% success rate. dombu covers the Healthcare sector, focusing on stocks such as Hyloris Pharmaceuticals SA, MaaT Pharma, and Onward Medical N.V..
Currently, the analyst consensus on Hyloris Pharmaceuticals SA is a Moderate Buy with an average price target of €16.00.
Based on Hyloris Pharmaceuticals SA's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €2.7 million and a GAAP net loss of €1.43 million. In comparison, last year the company earned a revenue of €1.53 million and had a GAAP net loss of €4.37 million
